- All sections
- C - Chemistry; metallurgy
- C07D - Heterocyclic compounds
- C07D 211/62 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
Patent holdings for IPC class C07D 211/62
Total number of patents in this class: 453
10-year publication summary
|
38
|
47
|
38
|
35
|
32
|
27
|
23
|
22
|
29
|
4
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Theravance Biopharma R&D IP, LLC | 550 |
30 |
| Biogen MA Inc. | 926 |
19 |
| Novartis AG | 11238 |
15 |
| Eisai R&D Management Co., Ltd. | 1304 |
11 |
| The Broad Institute, Inc. | 1584 |
10 |
| ChemoCentryx, Inc. | 400 |
9 |
| The Regents of the University of California | 18943 |
8 |
| Bayer Cropscience AG | 2241 |
8 |
| Massachusetts Institute of Technology | 9795 |
8 |
| The Board of Trustees of the University of Illinois | 2623 |
8 |
| Astellas Pharma Inc. | 1145 |
8 |
| Boehringer Ingelheim International GmbH | 4629 |
7 |
| The General Hospital Corporation | 4517 |
7 |
| Bristol-myers Squibb Company | 5080 |
6 |
| Eli Lilly and Company | 3645 |
6 |
| Global Blood Therapeutics, Inc. | 180 |
6 |
| Mitsubishi Tanabe Pharma Corporation | 579 |
6 |
| Merck Sharp & Dohme Corp. | 2247 |
5 |
| Takeda Pharmaceutical Company Limited | 2961 |
5 |
| Alkermes Pharma Ireland Limited | 307 |
5 |
| Other owners | 266 |